Multivariate Analysis of Effects of VEGF on Outcome
| Outcome . | Independent Predictors of Unfavorable Outcome . | P Value . |
|---|---|---|
| CR | VEGF | .048 |
| Increasing age | .049 | |
| Zubrod performance status 3-4 | .042 | |
| Treatment with Fludarabine | .002 | |
| DFS | VEGF | .010 |
| −5/−7 | .003 | |
| Increasing age | .017 | |
| Treatment with Fludarabine | .011 | |
| Treatment in laminar air flow room | .027 | |
| DFS from CR | VEGF | .002 |
| −5/−7 | <.0001 | |
| Survival | VEGF | .019 |
| Increasing age | <.0001 | |
| Treatment with Fludarabine | .04 | |
| Treatment in laminar air flow room | .002 |
| Outcome . | Independent Predictors of Unfavorable Outcome . | P Value . |
|---|---|---|
| CR | VEGF | .048 |
| Increasing age | .049 | |
| Zubrod performance status 3-4 | .042 | |
| Treatment with Fludarabine | .002 | |
| DFS | VEGF | .010 |
| −5/−7 | .003 | |
| Increasing age | .017 | |
| Treatment with Fludarabine | .011 | |
| Treatment in laminar air flow room | .027 | |
| DFS from CR | VEGF | .002 |
| −5/−7 | <.0001 | |
| Survival | VEGF | .019 |
| Increasing age | <.0001 | |
| Treatment with Fludarabine | .04 | |
| Treatment in laminar air flow room | .002 |